Monday, May 6, 2013

Entrevista a Javier Díaz-Nido


Radio interview to Javier Diaz-Nido, Spanish Researcher on Friedreich's Ataxia
(Spanish)

Manuel Seara ha hablado sobre ataxia con Javier Díaz-Nido en el programa A hombros de gigantes de RNE, profesor titular de Biología Molecular de la Universidad Autónoma de Madrid y experto en la ataxia de Friedreich.

http://www.rtve.es/alacarta/audios/a-hombros-de-gigantes/hombros-gigantes-entrevista-javier-diaz-nido/1803448/

Sunday, May 5, 2013

Thursday, May 2, 2013

Radial diffusivity in the cerebellar peduncles correlates with clinical severity in Friedreich ataxia

Radial diffusivity in the cerebellar peduncles correlates with clinical severity in Friedreich ataxia. Christian Clemm von Hohenberg, Michael F. Schocke, Marlene C. Wigand, Wolfgang Nachbauer, Charles RG Guttmann, Marek Kubicki, Martha E. Shenton, Sylvia Boesch, Karl Egger.
Neurological Sciences, May 2013. DOI 10.1007/s10072-013-1402-0

Keywords: Friedreich ataxia, Magnetic resonance imaging, Diffusion-tensor imaging, Tract-based spatial statistics, Cerebellar peduncle, Biomarker.

Wednesday, May 1, 2013

Heme Levels Are Increased in Human Failing Hearts

Heme Levels Are Increased in Human Failing Hearts. Arineh Khechaduri, MS; Marina Bayeva, PhD; Hsiang-Chun Chang, BA; Hossein Ardehali, MD, PhD.;
J Am Coll Cardiol. 2013;61(18):1884-1893. doi:10.1016/j.jacc.2013.02.012

Similarly, aggregation of iron inside the mitochondria has been observed in the hearts of Friedreich’s ataxia patients, who develop progressive and lethal cardiac dysfunction. Thus, maintenance of iron balance inside the heart appears to be critical for its function, but it remains unknown how iron regulation is altered in failing human hearts.

Saturday, April 27, 2013

Triple Therapy with Darbepoetin Alfa, Idebenone, and Riboflavin in Friedreich’s Ataxia: an Open-Label Trial

Triple Therapy with Darbepoetin Alfa, Idebenone, and Riboflavin in Friedreich’s Ataxia: an Open-Label Trial. Javier Arpa, Irene Sanz-Gallego, Francisco J. Rodríguez-de-Rivera, Francisco J. Domínguez-Melcón, Daniel Prefasi, Javier Oliva-Navarro, Mar Moreno-Yangüela, Samuel I. Pascual-Pascual. The Cerebellum April 2013 DOI 10.1007/s12311-013-0482-y



Long-term statistically nonsignificant improvement of LVMI and stability of the echocardiographic parameters could be considered. Triple therapy may slow disease progression of FRDA.

Progress in gene therapy for neurological disorders

Progress in gene therapy for neurological disorders. Michele Simonato, Jean Bennett, Nicholas M. Boulis, Maria G. Castro, David J. Fink, William F. Goins, Steven J. Gray, Pedro R. Lowenstein, Luk H. Vandenberghe, Thomas J. Wilson, John H. Wolfe & Joseph C. Glorioso; Nature Reviews Neurology , | doi:10.1038/nrneurol.2013.56

Standard medical and surgical practice has not proved effective in curing or treating these diseases, and appropriate pharmaceuticals do not exist or are insufficient to slow disease progression. Gene therapy is emerging as a powerful approach with potential to treat and even cure some of the most common diseases of the nervous system.

Erythropoietin receptor (EpoR) agonism to treat a wide range of diseases.

Erythropoietin receptor (EpoR) agonism to treat a wide range of diseases. Sanchis-Gomar F, Perez-Quilis C, Lippi G.; Mol Med. 2013 Apr 11. doi: 10.2119/molmed.2013.00025.

Keywords: Erythropoietin receptor (EpoR), pleitropic actions, heart and cardiovascular diseases, neurodegenerative disorders (Parkinson and Alzheimer), spinal cord injury, stroke, diabetic retinopathy, rare diseases (Friedreich ataxia) side effects, non-hematopoietic EpoR agonists drugs (asialoEpo, Cepo and ARA 290)

Friday, April 26, 2013

Hereditary Ataxia and Spastic Paraplegia in Portugal: A Population-Based Prevalence Study.

Hereditary Ataxia and Spastic Paraplegia in Portugal: A Population-Based Prevalence Study. Coutinho P, Ruano L, Loureiro JL, Cruz VT, Barros J, Tuna A, Barbot C, Guimarães J, Alonso I, Silveira I, Sequeiros J, Marques Neves J, Serrano P, Silva MC
JAMA Neurology [2013:1-10]

Friedreich ataxia (prevalence, 1.0 per 100 000 population)

Wednesday, April 24, 2013

Saturday, April 20, 2013

New scholarship research into Friedreich Ataxia, heart and eye dysfunction

CERA student receives prestigious Gustav Nossal Scholarship for his research into Friedreich Ataxia .
CERA (Centre for Eye Research Australia).09 April, 2013

Duncan is a PhD student in CERA's Neuroregeneration Research Unit, he uses stem cells generated in the laboratory from FRDA patients' own skin, to grow certain types of cells found in the heart and eye. These cells will be used to better understand the pathology of FRDA, to conduct basic research on the disease and to test new drugs, prior to conducting clinical trials.